The EdU assay revealed that either shFAK or FAK inhibitor administration significantly diminished the enhanced proliferative capacity of HNSCC cells driven by TNS4 overexpression (Figure 4A). This evidence concerns the gene PTK2 and head and neck squamous cell carcinoma.